November 10, 2011
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer

SymBio Initiates Japan Phase 2 Trial of Bendamustine HCl (SyB L-0501)
in Frontline Low-grade Non-Hodgkin’s Lymphoma and Mantle Cell Lymphoma
TOKYO, Japan, November 10, 2011 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, President &CEO: Fuminori Yoshida, “SymBio”) announced that it initiated a phase 2 clinical trial on November 9 forbendamustine hydrochloride (SyB L-0501) in frontline low-grade non-Hodgkin’s lymphoma (NHL) and mantle
cell lymphoma (MCL) patients in Japan. Patient enrollment in this multicenter open-label trial is underway.
In Japan, SymBio received marketing approval of TREAKISYM® (SyB L-0501) in October, 2010, for thetreatment of patients with refractory/relapsed low-grade NHL and MCL. Working with Eisai Co. Ltd.,TREAKISYM® is expected to achieve rapid market penetration in Japan.
The number of low-grade non-Hodgkin’s lymphoma1 patients in Japan is estimated to be around 11,000,including 4,000 refractory/relapsed patients and 7,000 untreated patients. Currently, R-CHOP2 is prescribed
as a standard therapy, however, clinical trial results in the U.S. and Europe have shown superiority of R-B3
over R-CHOP in terms of safety and efficacy, leading to the inclusion of R-B in National Comprehensive Cancer
4Network (NCCN) guidelines used by US physicians in prescribing oncology drugs.

SymBio has also initiated phase 2 trials for SyB L-0501 in refractory/relapsed intermediate and high-grade
non-Hodgkin’s lymphoma, and frontline multiple myeloma patients. The Company continues to pursue otherindications for TREAKISYM® in the hematology space as nimbly as possible in order to maximize the potentialof this ‘pipeline within a molecule’ and address other unmet medical needs in patients.

SymBio’s financial forecast for FY 2011 will not be revised due to the acceptance of clinical trial notification.

[Please read the following to learn more about Glossary, Bendamustine Hydrochloride (SyB L-0501),
and SymBio Pharmaceuticals][Contact]

Hiroki Maekawa
Board Director, Corporate Officer, Chief Financial Officer
Tel: +081(0)3 5472 1125

Note to Editors

Glossary
1 Non-Hodgkin’s lymphoma: Lymphatic malignancy except for Hodgkin’s lymphoma. In Japan, most of lymphomas isnon-Hodgkin lymphoma. Non-Hodgkin’s lymphoma is categorized by progression, which means lymphoma progressing
annually is low-grade and monthly is mid and high grade.
2 R-CHOP: Combination therapy of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone.
3 R-B: Combination therapy of Rituximab and Bendamustine
4 Network (NCCN) guidelines: An alliance of 21 of the world's leading cancer centers, these guidelines are widely
recognized and used as the standard for clinical policy in oncology by clinicians and payors.

About Bendamustine Hydrochloride (SyB L-0501)
Bendamustine was first synthesized in the early 1960s in former ‘East Germany’ by Jenapharm, and iscurrently marketed in Germany under the brand name “Ribomustin®” as a treatment for non-Hodgkin’slymphoma, multiple myeloma and chronic lymphocytic leukemia. Mundipharma has received market
authorization in a number of EU countries for bendamustine under the brand name “Levact®.” In the UnitedStates, the drug has been approved by the U.S. Food and Drug Administration and is marketed asTREANDA® for the treatment of chronic lymphocytic leukemia and relapsed indolent B-cell non-Hodgkin's
lymphoma. SymBio Pharmaceuticals Limited originally acquired the exclusive right from Astellas DeutschlandGmbH (Headquarters: Munich, Germany, formerly Astellas Pharma GmbH) to develop and commercialize
bendamustine in Japan (December, 2005), followed by signature of a second license agreement for theexclusive right to China/Hong Kong, Taiwan, South Korea and Singapore (March, 2007).
About TREAKISYM®
Product Name:
TREAKISYM® for Injection, for intravenous infusion 100 mg
Generic Name:bendamustine hydrochloride
Indications and Usage:
For the treatment of relapsed or refractory forms of the following indications:・ Low-grade B-cell non-Hodgkin’s lymphoma
・ Mantle cell lymphoma
Dosage and Administration:
The standard adult dose of bendamustine hydrochloride is 120 mg/m2 infused intravenously
over 60 minutes on Days 1 and 2 of repeated 21-day cycles. The dose may be reduced as
deemed appropriate according to the patient’s condition.
About SymBio Pharmaceuticals Limited
SymBio Pharmaceuticals Ltd. was established in March, 2005 by Fuminori Yoshida, who previously served
concurrently as Corporate VP of Amgen Ltd. and founding President of Amgen Japan (currently Takeda BioDevelopment Center Limited). The company’s underlying corporate mission is “delivering hope to patients inneed” as it aspires to be a leading specialty pharmaceutical company in Asia Pacific dedicated to addressing
underserved medical needs in the areas of oncology, hematology and autoimmune disease.